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1. Introduction 
Kidneys play an important role in maintenance of the calcium and phosphorus balance. 
Renal failure is associated with disorders of all phases of the phosphorus and calcium 
turnover. The decrease of glomerular filtration rate (GFR) under 60 ml/min/1.73 m2 is 
associated with phosphorus filtration rate decrease with further elevation of its serum level 
that results in parathyroid hormone (PTH) secretion stimulation. PTH suppresses 
phosphorus reabsorption; therefore, it returns its serum level to normal. However, when the 
GFR falls below the 30 ml/min/1.73 m2 level, this mechanism becomes ineffective and 
persistent hyperphosphatemia develops. The latter enhances the PTH secretion. 
Hyperphosphatemia is associated with inhibition of 1ǂ-hydroxylase effect in proximal renal 
tubules and the decrease of serum 1,25(OH)2D3 (calcitriol) level. Calcitriol deficiency results 
in calcium absorption disorders in small intestine; as a result, hypocalcemia develops. 
Persistent hypocalcemia results in parathyroid glands hyperplasia (PTGH) that is associated 
with excessive PTH production and secretion. PTH hyper-production and 
hyperphosphatemia are the manifestations of secondary hyper-parathyroidism (SHPT). 
Hypocalcemia, vitamin D deficiency and hyperphosphatemia are the main factors 
responsible for secondary hyperparathyroidism. Hypocalcemia, vitamin D deficiency and 
hyperphosphatemia develop at the initial stage or renal dysfunction – Chronic Kidney 
Disease (CKD) III (GFR 60-30 ml/min/1.73 m2); they progress with the increasing severity 
of renal failure  (GFR 29-15 ml/min/1.73 m2, CKD IV-V). Disorders of calcium and 
phosphorus balance associated with CKD result in bone diseases, generally called renal 
osteodystrophy. At the same time numerous cohort  studies have broadened the focus of 
CKD-related mineral and bone disorders to include cardiovascular disease ( which is the 
leading cause of death in patients at all stages of CKD). All three of these processes  
(abnormal mineral metabolism, abnormal bone and extra skeletal calcification) are closely 
interrelated and together make a major contribution to the morbidity and mortality of 
patients with CKD. 
Since the publication of the 2003 K/DOQI guidelines for bone and mineral metabolism, 
there has been tremendous advancement in our understanding of mineral metabolism in 
CKD patients. Major modifications of K/DOQI bone guidelines are essential and should 
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reflect our improved understanding of calcium and phosphorus metabolism. At the same 
time there is a desperate need for randomized trials for  better informed decision making 
and further optimization of care of CKD patients. 
The aim of the review is to provide a literature summary concerning the diagnosis and 
treatment of mineral metabolism disorders in CKD, which will serve an action plan for 
clinicians. 
2. Methods  
Literature searches were made of 10 major databases, among which were: Medline, Pubmed, 
Embase, Cochrane Library and CINAHL. The search was carried out to capture all articles 
relevant to the topic of CKD and mineral metabolism, bone disorders, and 
vascular/valvular calcification/. This search encompassed original articles, systematic 
reviews and meta-analyses. 
2.1 Agreed criteria for article inclusion have been 
- Articles should be full-text. Brief publications and abstracts were not  included. 
- Research should be at least 10 patients in each group. The minimum mean duration of 
study was  6 months. 
- Analyzed literature over 15 years. 
- The article is detailed research protocol for assessing of its quality 
- Patient examination and treatment protocol must meet K / DOQI guidelines protocol 
and KDIGO Clinical Practice for the Diagnosis, Evaluation, Prevention, and Treatment 
of Chronic Kidney Disease-Mineral and Bone Disorder  (CKD-MBD) ---First of all 
articles included a high level of evidence: 
• Randomized controlled trials 
• Prospective nonrandomized without matching controlled trials 
• Retrospective nonrandomized without matching controlled trials 
Today, these are standard principles in dealing with the introduction into clinical practice of 
new diagnosis and treatment methods. 
3. Pathogenesis of calcium and phosphorus turnover disorders in patients 
with CKD stages III-IV 
3.1 Hyperphosphatemia 
The serum level of phosphorus is based on the ratio of phosphorus absorption in gastro-
intestinal tract, mobilization rate in bones (bones serve as calcium and phosphorus reservoirs) 
and renal excretion. Dietary consumption of phosphorus is about 1000-1200 mg; about 800 mg 
of this amount is being absorbed in intestines (phosphorus turnover pool). The turnover pool 
is subdivided into cell cytoplasm compartment (70%), bone compartment (29%) and serum 
(less than 1%). Phosphorus balance is maintained by kidneys. Usually, kidneys filter about 9 g 
of phosphorus; about 8 g (90%) are reabsorbed in proximal tubules. Reabsorption is mediated 
by three transporters:  Na+/Pi- co-transporters types I, II and III [Ermolenko, 2009; Lederer, 
2011]. Transporters types I and II are located on the apical membranes of canalicular 
epithelium cells, while transporter type III is located on their basal membrane. Phosphorus 
reabsorption is associated with Na+ transport and depends on the number of  Na+/Pi- co-
transporter molecules on the cell’s membrane [ Farrow E, 2010; Lederer, 2011; Quarles,2008].  
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High level of extracellular phosphorus is associated with suppression of 1ǂOHD3-
hydroxylase (enzyme mediating conversion of 25(OH)D3 to 1,25(OH)2D3); low level of 
phosphorus results in  opposite effect. The effect of extracellular phosphorus on enzyme’s 
activity is independent of PTH or  Na+/Pi co-transporter. CKD can also result in 
hypophosphatemia associated with malabsorption, excessive use of phosphate-binding 
drugs, hyperventilation, vitamin D deficiency or long term glucocorticoid treatment. 
Chronic phosphate deficiency results in increased renal reabsorption mediated by formation 
of new Na+/Pi co-transporter. It is associated with simultaneous 1,25(OH)2D3 
hyperproduction and increased plasma Ca2+ level . Increased intestinal absorption of Ca2+ 
and renal reabsorption result in suppression of PTH secretion and enhanced  
renal reabsorption of phosphorus. Therefore, the factors regulating  phosphorus and 
calcium metabolism are interlinked. Calcitriol increases the phosphorus absorption  
through enhancement of its uptake by vesicles of enterocytes brush border [Hruska, 2008; 
Lederer, 2011 ]. Persistent hyperphosphatemia is found when GFR falls below 60 
ml/min/1.73 m2. Severe renal dysfunction (GFR under 30 ml/min/1.73 m2) is associated 
with permanent hyperphosphatemia. CKD-associated phosphorus retention mediates 
hypocalcemia both through direct effect of hyperphosphatemia on plasma level of calcium, 
and indirectly – through an effect on parathyroid glands. The results of experiments 
demonstrate that hyperphosphatemia can stimulate secondary hyperparathyroidism; the 
process is unrelated to hypocalcemia and/or vitamin D3 deficiency. Therefore, in patients 
with CKD the plasma phosphorus level should be 2.7-4.6 mg/dl (0.87 – 1.49 mmol/l); and 
3.5-5.5 mg/dl (1.13 – 1.78) in patients with CKD V [Fucumoto , 2008; Gutierrez , 2005; 
Hruska, 2008; Lederer, 2011; National kidney Foundation. K/DOQI Clinical Practice 
Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease., 2003; 
KDIGO,2009].  
3.2 Hypocalcemia 
Dietary consumption of calcium in adults is 1.0 – 1.5 g/day. Most of this amount is absorbed 
in duodenum and proximal part of small intestine. Calcium absorption rate depends on its 
content in food and bone mineralization rate. Administration of calcium-based drugs with 
meals is associated with better absorption rate [Ermolenko, 2009; Fucumoto, 2008; National 
kidney Foundation. K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease 
in Chronic Kidney Disease, 2003; KDIGO, 2009 ]. Renal filtration rate is about 5-7 g/day; 
about 95-97.5% of calcium is reabsorbed in renal tubules. Bone tissue is the main calcium 
reservoir, containing up to 98% of total body calcium. In serum, about one-half of calcium is 
represented by free ions, while the rest of calcium is bound to plasma proteins (mainly with 
albumin) or to other cations. Plasma level of calcium ions regulates all its biological effects. 
CKD IV-V is associated with gastro-intestinal absorption disorders resulting in low calcium 
absorption that results in low plasma level of total calcium or calcium ions [Ermolenko, 
2009; Fucumoto , 2008]. Meat and dairy products are the main sources of dietary calcium. 
Dietary calcium is protein-bound. Calcium is released in GIT by proteases. The Ca2+ 
absorption rate in duodenum depends on the level of calcium-binding protein – calbindin – 
in cytoplasm of the enterocytes. Active transport of Ca2+ ions is regulated by calcitriol that 
interacts with intra-cellular receptors, which controls the transcription of over 60 genes. 
These genes encode calbindin and Ca2+ pump proteins [Foley ,1998; Parfey ,2000; 
KDIGO,2009]. The factors influencing intestinal absorption of calcium are listed in Table 1.  
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Increase Decrease 
Vitamin D Age 
Low calcium uptake High calcium uptake 
High sodium uptake Low sodium uptake 
Phosphate deficiency Glucocorticosteroids 
Growth hormone Phosphate loading 
Estrogens Thyroid hormones 
Pregnancy, lactation Metabolic acidosis 
Furosemide Thiazide diuretics 
Table 1. Factors influencing intestinal absorption of calcium  
In healthy patients Ca2+ excretion rate is 40-300 mg/day [Ermolenko, 2009; K/DOQI 
Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease, 
2003; Quarles, 2008 ]. Hypophosphatemia results in decrease in plasma calcium ions level , 
both through direct binding and decreased renal production of  1,25(OH)2D3. Calcium is the 
main regulator of PTH secretion. Even short-term hypocalcemia results in increased PTH 
secretion due to activation of Ca-receptors located on the surface of parathyroid gland. 
Persistent hypocalcemia results in increased level of PTH matrix RNA and pre-pro-PTH 
gene transcription that is associated with PTH hyperproduction and secondary 
hyperparathyroidism. The latter results in PTH hyper-production and hyper-secretion. In 
hypocalcemia PTH stimulates the production of 1,25(OH)2D3 in kidneys that is associated 
with increased calcium absorption in gastro-intestinal tract [Fucumoto , 2008; Gutierrez, 
2005]. In CKD IV-V the relationship of calcium level and PTH secretion is disordered, 
therefore, higher level of calcium ions is required to suppress the PTH production. 
Therefore, it is preferable to maintain the serum level of calcium ions within the ULN 
[Ermolenko, 2009 ; National kidney Foundation. K/DOQI Clinical Practice Guidelines for 
Bone Metabolism and Disease in Chronic Kidney Disease, 2003; KDIGO,2009, Patel,2009].  
The calcium level in dialysis fluid for patients receiving haemo- and peritoneal dialysis 
should be 2.5 mEq/l (1.25 mmol/l). In patients with CKD IV-V the adenylate-cyclase of 
parathyroid glands is less sensitive to calcium inhibitory effect. Glucocorticoids suppress 
calcium absorption by inhibiting the transformation of 25OHD3 to 1,25(OH)2D3; phosphates 
provide the same effect by forming insoluble complexes and oxalates [National kidney 
Foundation. K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in 
Chronic Kidney Disease, 2003; KDIGO,2009]. 
3.3 PTH and calcitonin hyperproduction 
3.3.1 PTH molecule (structure and effects) 
PTH molecule contains 84 amino acid derivates (1-84) and contains short N-terminal 
fragment (PTH 1-34) and long C-terminal fragment (PTH 7-84). The molecular weight of 
PTH is 9425 Da. The gene mediating PTH synthesis is located on 11-th chromosome. Both 
whole PTH molecule and its N-terminal fragment possess biological effects [Block, 1998; 
Kestenbaum ,2005, Lederer, 2011].  
PTH regulates the plasma level of Ca2+. Elevated Ca2+ plasma level suppresses the PTH 
synthesis [Block ,1998; Kestenbaum ,2005; Marchais,1999; Slinin, 2005]. This feedback 
enables the constant plasma level of Ca2+. PTH maintains constant Ca2+ plasma level 
through the following mechanisms:  
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• Stimulation of bone tissue resorption resulting in calcium passage to blood. 
• Stimulation of renal reabsorption of calcium, resulting in lower excretion in  urine.  
• Increase of calcium absorption in small intestine (mediated by 1,25(Ǽǻ)2D3 synthesis 
stimulation).  
Calcium level is regulated mainly by PTH-mediated effect on bone tissue; to a lesser extent 
it is regulated by effect on renal excretion of calcium. Long-term maintenance of calcium 
balance is mediated mainly by the PTH effect on 1,25(Ǽǻ)2D3 synthesis and, therefore, on 
the rate of calcium absorption in gastro-intestinal tract. The daily level of blood and bone 
tissue calcium turnover is about 500 mg. PTH is the main regulator of this turnover [Block 
,2007; Quarles,2008]. 
PTH provides several direct and indirect effects on bone tissue. Persistent PTH level 
elevation results in bone tissue cells increase (primarily – of the osteoclasts) and intensive 
bone remodeling. The rate of PTH secretion by parathyroid glands depends on plasma level 
of Ca2+. Magnesium provides similar but less pronounced effect on PTH secretion. In fact, 
the physiological changes of magnesium level do not impact the PTH secretion; however, 
pronounced decrease of intra-cellular magnesium level results in increased PTH secretion 
[Block ,2007; Craver,2007; Lederer, 2011]. 
The effect of Ca2+ on PTH secretion is mediated through its interaction with Ca receptors 
(CaR) that are bound to G-proteins and have a large extracellular domain for binding to 
low-molecular weight ligands. Activation of receptors associated with high Ca2+ plasma 
level suppresses the PTH secretion. This inhibitory effect is mediated by secondary 
facilitators – inositol 1,4,5-triphosphate (IF3) and 1,2-diacylglycerine. CaR are found in 
parathyroid glands cells, in C-cells of the thyroid gland that secrete calcitonin, and also in 
brain and kidney cells. C-terminal fragments provide the anabolic effect on bone tissue 
[Ermolenko, 2009; Ketteler, 2011]. Normally, PTH and its fragments are excreted by kidneys 
and metabolized in cells of terminal tubules. Parathyroid gland produces both the complete 
PTH molecules, and their fragments. Complete molecules are subject to faster plasma 
elimination compared to C-terminal fragments. GFR decrease and metabolism disorders 
associated with CKD result in accumulation of C-terminal fragments in plasma. Intact PTH 
and its fragments can’t be determined by I generation PTH tests; their results reflect the 
levels of inactive fragments. Recently, immuno-radiometry with double kit of antibodies to 
N-terminal and C-terminal epitopes has been introduced to measure the iPTH level. CKD 
IV-V is associated with iPTH level increase mostly due to hyper-secretion. iPTH hyper-
secretion is promoted by Pi level elevation and decrease of serum Ca2+ level in extracellular 
fluid. iPTH interacts with membrane adenylatecyclase-bound receptor in proximal and 
distal renal tubules and causes phosphaturia, hypophosphatemia and enhances calcium 
reabsorption in distal renal tubules [Kestenbaum, 2005; Marchais, 1999; Lederer, 2011; 
Slinin, 2005]. Simultaneously, iPTH stimulates 1,25(OH)2D3 synthesis in renal parenchyma. 
The decrease of bone tissue sensitivity to iPTH-mediated calcemia is found at initial GFR 
decrease (<85 ml/min/1.73 m2). It does not regress during treatment. The same effect is 
found in many recipients of kidney grafts with decreased function (GFR under 70 
ml/min/1.73 m2) or in patients with acute renal failure. Acute renal failure is usually 
associated with hypocalcemia. It manifests during the oliguric stage and is present 
throughout the polyuric stage. Hypocalcemia regresses after the renal function 
normalization. Skeletal resistance to iPTH calcemic effect is associated with vitamin D3 
deficiency and down-regulation of iPTH receptors. PTH effects osteogenesis through 
activation of osteoblasts while bone resorption is mediated through activation of osteoclasts. 
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However, osteoclasts have no PTH receptors, therefore, their stimulation is mediated by 
release of cytokines by osteoblasts. In experiments, the stimulation of osteoclast-mediated 
bone resorption by PTH was found in cell cultures containing both osteoclasts and 
osteoblasts [Block, 2007; Lederer, 2011; Marchais, 1999]. Cytokines IGF-1, IL-6, G-CSF 
mediate proliferation and differentiation of osteoclasts progenitor cells. Large multi-nuclear 
osteoclasts are formed. They start secreting organic acids and hydrolytic enzymes that 
dissolve the mineral matrix and organic substance of bone tissue. This process results in 
release of phosphorus, calcium and bicarbonate to extra-cellular fluid. Osteoblasts produce 
organic components (mostly – type I collagen); however, iPTH-mediated activation of 
resorption processes is more pronounced compared to activation of bone synthesis. As 
hypocalcemia develops, PTH removes calcium from bone tissue in order to maintain its 
constant level in extra-cellular fluid. Even mild elevation of iPTH level results in activation 
of mature osteoclasts and bone tissue resorption [Block , 1998; Kestenbaum ,2005; Lederer, 
2011; Marchais,1999; Slinin, 2005].  
3.3.2 Calcitonin 
Calcitonin is secreted by the inter-follicular cells of thyroid gland. In 30% patients with 
terminal CKD elevated plasma level of calcitonin is found. Calcitonin provides phosphaturic 
effect by inhibiting the phosphates reabsorption in proximal convoluted tubules and 
enhances the activity of 1ǂ-hydroxylase by stimulating the production of 1,25(OH)2D3. 
Calcitonin decreases the Ca2+ serum and extra-cellular fluid levels, reduces the number of 
osteoclasts and suppresses their activity, and inhibits the process of osteolysis [Ermolenko, 
2009; Lederer, 2011].   
3.4 Vitamin D3 deficiency 
Calcitriol (1,25-dihydroxycholecalciferol) is formed from vitamin D3 (cholecalciferol) as a 
result of hydroxylation (addition of the OH group) to position 25 (in liver) or to position 1 
(in proximal convoluted tubules of kidneys); the hydroxylation process is mediated by ǂ1-
hydroxylase. In kidneys calcitriol induces Ca2+ and Pi reabsorption. In small intestine 
calcitriol enhances the production of calcium-binding protein that enhances Ca2+ 
absorption. In bone tissue calcitriol stimulates pre-osteoclasts proliferation and 
differentiation. Calcitriol induces the synthesis of organic bone matrix and regulates the 
process of bone tissue mineralization [Craver , 2007; Liu ,2006;Quarles,2008]. In patients 
with CKD III relative deficiency of 1,25(OH)2D3 is found. When the GFR falls below 50 
ml/min/1.73 m2 (in children) or 30 ml/min/1.73 m2 (in adults) relative deficiency is 
followed by absolute calcitriol deficiency [Craver , 2007; Liu ,2006; Zemchencov , 2009]. CKD 
progression is associated with the decrease of vitamin D receptors (VDR) and Ca-receptors 
of parathyroid gland that is associated with decreased sensitivity to effects of 1,25(OH)2D3 
and Ca2+. Patients with CKD IV-V have low 1,25(OH)2D3 plasma level, associated with 
renal hydroxylation process disorders. Such patients develop 1,25(OH)2D3 deficiency and 
are resistant to its effect. In patients with removed kidneys and patients receiving dialysis 
usually the plasma level of 1,25(OH)2D3 can’t be detected by standard analyses. Low plasma 
level of 25-hydroxy vitamin D [25(OH)D3] is found in CKD patients with nephrotic 
proteinuria due to 25(OH)D3 losses with urine, in patients receiving peritoneal dialysis – due 
to PTH diffusion into peritoneal solution and in patients with low dietary uptake of vitamin 
D. Limited dietary uptake of phosphorus associated with decreased GFR in CKD patients 
results in elevated plasma 1,25(OH)2D3 level and enhanced response of target organs to 
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calcitriol effect. Calcitriol inhibits the activity of PTH through direct effect on PTH gene. It 
inhibits gene transcription and PTH synthesis and stimulates the sensitivity of calcium 
receptors in parathyroid cells. The results of experiments prove that calcitriol deficiency can 
initiate secondary hyperparathyroidism even without hypocalcemia. Calcitriol deficiency 
results in calcium intestinal absorption disorders and suppression of calcemia effect on 
iPTH. Hypocalcemia results in hyperparathyroidism [Ketteler,2011; Lederer, 2011; Liu ,2006; 
Zemchencov , 2009]. 
3.5 CKD-associated ectopic mineralization 
Several authors consider CKD-associated hyperphosphatemia to be a special syndrome 
associated with specific bone remodeling, heterotopic mineralization and cardiovascular 
complications [Ermolenko, 2009; Hruska, 2008; National kidney Foundation. K/DOQI 
Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease, 
2003, KDIGO,2009; Zemchencov, 2009].  
In patients with CKD and hyperphosphatemia the rate of arterial hypertension and mean 
blood pressure levels are significantly higher compared to patients with normal plasma 
level of phosphorus. These conditions are associated with vascular adaptation system 
disorders; therefore, high blood pressure can result in significant mechanical loading and 
loss of arterial wall elasticity [London, 2000; Parfey, 2000 ]. Direct statistically significant 
correlation between high Ca × P index (over 70 mg2/dl2) and the rate of hypertrophic 
cardiomyopathy [Block ,1998; Kestenbaum ,2005; Marchais,1999; Slinin, 2005] has been 
demonstrated. Hypertrophic cardiomyopathy along with myocardial ischemia are the main 
reasons of congestive heart  failure in patients with CKD. Moreover, high phosphorus levels 
promote non-atherosclerotic arterial calcification associated with vascular smooth muscles 
cells (VSMC) transformation into osteogenous phenotype [Lederer, 2011; Shanahan C, 1994].  
CKD-associated hyperphosphatemia development is also associated with bone tissue 
remodeling. CKD patients have a broad spectrum of bone remodeling; however they have 
similar features – excessive bone tissue resorption compared to formation. The experimental 
data prove that hyperphosphatemia is associated with block of phosphate reservoir function 
of bone tissue [National kidney Foundation; K/DOQI Clinical Practice Guidelines for Bone 
Metabolism and Disease in Chronic Kidney Disease, 2003; Shanahan C,1994; Volgina, 2004]. 
However, the requirement of phosphorus in bone tissue increases. It results in phosphorus 
plasma level elevation. Soft tissues and blood vessels become new phosphorus reservoirs. 
Formation of phosphorus reservoirs in the walls of arteries result in their higher rigidity 
[Lederer, 2011; London,2000, National kidney Foundation. K/DOQI Clinical Practice 
Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease, 2003; KDIGO,2009; 
Parfrey,2000; Zemchencov, 2009].  
Recent studies have demonstrated that CKD patients with hyperphosphatemia (>6.5 mg/dl) 
have a higher risk of cardiovascular mortality compared to patients with lower phosphorus 
levels (<6.5 mg/dl). Therefore, maintenance of serum phosphorus level within <6.5 mg/dl 
limit seems to be an important therapeutic objective in these patients [Davies , 2003, 2005; 
National kidney Foundation. K/DOQI Clinical Practice Guidelines for Bone Metabolism 
and Disease in Chronic Kidney Disease, 2003; KDIGO,2009; Pletcher,2004; Wang,2006].  
Two types of vascular calcification are typical for CKD: calcification of atherosclerotic neo-
intimal plaques (intima calcification) and arterial tunica media calcification (media 
calcification) [London, 2000; Wang, 2006]. Both types of vascular calcification progress along 
with advancing CKD. Coronary arteries intimal calcification is the risk factor for of 
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myocardial infarction [London, 2000; National kidney Foundation. K/DOQI Clinical 
Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease, 2003; 
KDIGO, 2009]. In CKD patients the calcification of media is characterized by extensive 
diffuse lesions (atherosclerosis of Moenkenberg). It results in coronary damage with acute 
coronary syndrome development, ectopic calcification of large arteries with pulse wave 
speed increase. It is manifested by increased systolic and pulse pressure and rapid left 
ventricle hypertrophy [Davies, 2005; London, 2000; Pletcher, 2004; Townsend, 2011; Wang, 
2006]. Heart calcification is manifested mostly by coronary arteries and heart valves 
calcinosis. They result in mitral valve failure or stenosis, arrhythmias, congestive heart 
failure; however, diffuse myocardial calcification can develop [London, 2000; National 
kidney Foundation. K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease 
in Chronic Kidney Disease, 2003; KDIGO,2009]. 
Blood vessels calcification risk factors: 
• Increased plasma levels of calcium and phosphorus 
• Ca2+ × Р5+ over 55 mg2/dl2 (5,5 mmol2/l2) 
• Elevated plasma level of iPTH 
• Fetuin A protein deficiency 
Blood vessels calcification compromises the formation of arterio-venous fistula and 
complicates kidney transplantation.  
Arteries of forearm, wrists, hands, lower extremities, abdominal cavity, thoracic cavity, 
pelvis and brain can undergo calcification [Ermolenko, 2009; National kidney Foundation. 
K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney 
Disease, 2003, Zemchencov, 2009]. 
Some patients develop severe vascular calcification so that the arteries can’t be pressed by 
the cuff during blood pressure measurement [London, 2000; National kidney Foundation. 
K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney 
Disease, 2003; Townsend, 2011].  
Electronic beam tomography is used to evaluate the calcium content in blood vessel walls 
[Davies ,2005; National kidney Foundation. K/DOQI Clinical Practice Guidelines for Bone 
Metabolism and Disease in Chronic Kidney Disease, 2003; KDIGO,2009; Wang, 2006]. 
The mechanisms of CKD-associated extra-osseous calcification are complicated and multi-
factorial. It has been demonstrated that VSMC and other vascular cells (pericytes, 
fibroblasts) can transform into osteoblast-like cells that produce hydroxy-apatite – the main 
mineral of bone tissue. In case of hyperphosphatemia smooth muscles of blood vessels 
accumulate phosphorus, express the genes of bone proteins and turn into areas of 
calcification [Nishimura , 2011; Shanahan,1994; Wang, 2006].    
Parathyroid gland hypertrophy in CKD patients contributes to severity of cardiovascular 
complications. It participates in development of myocardial fibrosis. iPTH elevates Ca2+ 
loading in cells and enhances the atherosclerotic changes. It also activates fibroblasts and 
provides direct impact on myocardium through myocardial cells metabolism disorders 
[Nishimura , 2011; Wang, 2006]. 
Myocardial fibrosis, coronary calcification and valves calcification promote the development 
and progression of systolic dysfunction and congestive heart failure. Left ventricle 
hypertrophy and increased Ca2+ level in myocardial cells result in diastolic dysfunction. 
These disorders are the main cause of cardiovascular mortality in CKD patients [London, 
2000;  Lederer, 2011; Nishimura , 2011; Pletcher,2004; Wang, 2006].  
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Hypoxia-induced 1-ǂ factor (HIF1-ǂ) and vascular endothelium growth factor are the main 
mediator of osteogenesis – angiogenesis interaction. It is considered that these factors induce 
vascular calcification through angiogenous signaling [Wang, 2006].  
The initial stage of arterial media calcification is associated with elastin degradation. Matrix 
metalloproteinases (MMp-2 and MMP-9) destroy elastin with formation of soluble elastin 
peptides. The latter bind to laminin-elastin receptors (ELR) on the surface of smooth muscles 
cells. Excessive expression of growth factor ǃ (TGF-ǃ) contributes to elastin destruction also. 
It is known that it enhances VSMC calcification rate and plays an important role in 
proliferation of osteoblasts. VSMC osteogenous transformation is activated by consecutive 
signaling of ELR, TGF-ǃ, and mitogen-activated proteinkinase. Calcification of media is 
associated with expression of several proteins related to osteogenesis: osteocalcin, 
osteopontin, matrix Ǆ-GLA (carboxyglutamic acid) protein  and osteoprotegrin [Isakova, 
2008; KDIGO,2009; Wang, 2006; Zemchencov, 2009].  
3.5.1 Relationship between osteogenesis and ectopic mineralization   
The relationships between osteogenesis and blood vessels calcification has been established. 
New factors produced by kidneys and bone tissues have been identified recently. The 
morphogenetic proteins (FGF-23 and Klotho) regulate homeostasis of phosphates, vitamin D 
and bone tissue mineralization. The level FGF-23 (fibroblasts growth factor 23, produced 
mostly by osteocytes) is increased even at the pre-dialysis stage of CKD [Gutiérrez, 2009; 
Jean, 2009; Pande , 2006; Razzaque 2008, 2009; Zemchencov, 2009]. 
The role of circulating FGF-23 level increase at various CKD stages is being studied. It has 
been established that enhanced production of FGF-23 during CKD stages II-III contributes to 
adaptive increase of phosphorus excretion and decrease of calcitriol production [Boekel 
,2008; Carpenter ,2005; Fang ,2001; Gutierrez ,2005, 2008; Kawata ,2007].  
Later, when the CKD IV-V results in GFR decrease, the elevated FGF-23 level is not enough 
to prevent hyperphosphatemia and hyperparathyroidism. Prospective studies [Gutiérrez, 
2009; Jean, 2009; Pande, 2006; Razzaque, 2009] demonstrate that elevated FGF-23 level in 
CKD patients at the stage of dialysis initiation is associated with mortality and vascular 
calcification independent of other risk factors or serum phosphorus and iPTH levels. 
Therefore, FGF-23 is the potential independent uremic toxin (Table 2).  
There are 2 types of Klotho protein – trans-membraneous and extra-cellular (secreted). It is 
produced and secreted by the cells of proximal renal tubules; the trans-membraneous 
protein is also produced by the parathyroid gland cells [Makoto ,2009; Sitara,2006].  
Makoto K demonstrated that trans-membraneous Klotho protein is a co-receptor of FGF-23 
and therefore contributes to regulation of phosphorus, calcium and vitamin D turnover. 
Extra-cellular part of Klotho protein that is secreted to systemic circulation acts as an 
endocrine factor and encodes multiple growth factors, including insulin-like growth factor 1 
and Wnt [Makoto, 2009].  
In CKD patients the expression rate of Klotho protein is decreased; therefore, it is considered 
to be the factor of renal protection. It is obvious that phosphorus turnover regulation is an 
important link of CKD pathogenesis. Early correction of hyperphosphatemia by influencing 
the endocrine interactions of the bones-kidneys-parathyroid glands axis mediated by Klotho 
and FGF-23 improves the quality of life in CKD patients [Boekel ,2008; Carpenter ,2005; Fang 
,2001; Gutiérrez, 2005, 2008, 2009; Jean,2009; Kawata ,2007; Pande , 2006; Razzaque 2008, 2009 ].  
In CKD patients the FGF-23 serum level elevation precedes hyperphosphatemia; therefore, 
resistance to FGF-23 can be one of the early signs of CKD-related metabolic disorders. It is 
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considered that development of resistance to FGF-23 is associated with decreased renal 
expression of Klotho protein. Therefore, low rate of renal expression of Klotho protein can 
be a prediction of poor long-term outcome in dialysis patients [Makoto , 2009].   
 
Authors Study results 
Razzaque M.S. [NDT 
20094 24(1): 4-7] 
Meta-analysis (10 studies). Most CKD patients demonstrated FGF-23
elevation prior to phosphorus level increase. In dialysis patients low
level of trans-membraneous Klotho expression in renal cells was
associated with poor cardiovascular prognosis 
Gutierrez O.M. Nev 
Engl J Med 2008; 
359(6): 584 - 592 
10 044 CKD patients, stage V. FGF-23 plasma level increase at initial
stage of dialysis was associated with a dose-related 1-year lethality
increase. Lethality hazard ratio (OR = 5.7) was higher compared to
hazard ratio for high phosphorus levels (OR = 1.2). 
Jean G et al NDT 2009; 
24(9); 2618-2620 
219 CKD stage V patients. FGF-23 level elevation (median 2740
RU/ml) at initial stages of dialysis was associated with
cardiovascular lethality not related to risk factors and plasma
phosphorus levels 
Gutierrez O.M. 
Circulation. 2009; 
119(19): 2545-2552 
162 CKD stage III-IV. Multivariate regressive analysis demonstrated
correlation of serum FGF-23 elevation and left ventricle infarction
(11% annual increase) or risk of coronaries calcification (2.4 fold
increase)  
Table 2. Relationship between elevated FGF-23 plasma level and poor CKD prognosis 
(results of prospective studies) 
FGF-23 level decreases along with the decline of hyperphosphatemia; therefore, low 
phosphate diet and phosphate binders seems to be an appropriate treatment strategy 
beginning from early CKD stages. These measures prevent the cardiovascular complications 
and secondary hyperparathyroidism in CKD patients. CKD patients demonstrate fasting 
FGF-23 level elevation, even without hyperphosphatemia and hypocalcemia. It is not clear 
yet, which CKD stage is associated with initial FGF-23 serum level increase; however, it is 
considered that FGF-23 hyper-production precedes plasma phosphorus and iPTH levels 
increase [Gutiérrez,2009;  Pande , 2006; Razzaque 2008, 2009].  
In most clinical studies plasma phosphorus, calcium, FGF-23 and iPTH levels were measured 
in fasting conditions. However, at early CKD stages without hyperphosphatemia and 
hypocalcemia plasma FGF-23 and iPTH levels are increased after meals. Urine excretion rate of 
phosphorus increase after meals was found in 13 CKD patients with normal fasting 
phosphorus and calcium levels and in 21 healthy volunteers despite normal plasma levels of 
phosphorus and FGF-23. Increased postprandial urine excretion of calcium was found in both 
groups; in CKD patients it was associated with significant calcium level decrease and elevation 
of iPTH plasma level. Therefore, FGF-23 does not impact the postprandial phosphaturia both 
in healthy volunteers and in CKD patients; however, CKD patients developed postprandial 
transient calcuria associated with relative hypocalcemia. This effect might reflect early stages 
of secondary hyperparathyroidism development [Craver ,2007; Razzaque ,2008].  
Recent studies demonstrate poor value of fasting iPTH evaluation in early diagnosing of 
secondary hyperparathyroidism; while assessment of FGF-23 plasma level (both fasting and 
postprandial) might be used as a sensitive screening test for secondary hyperparathyroidism 
development [Pande ,2006; Razzaque ,2009].  
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FGF-23 Elisa kit is used to evaluate FGF-23 serum level. Anti-Klotho polyclonal antibodies 
are used to evaluate Klotho levels in serum, spinal fluid, and urine. FGF-23/Klotho ratio in 
proximal renal tubules is assessed by immune-histochemical analysis [ Gutiérrez,2009; 
Razzaque ,2009].  
Therefore, in CKD patients phosphorus and calcium turnover disorders with 
hyperphosphatemia, vascular calcification, left ventricle hypertrophy are also mediated by 
newly discovered regulation mechanisms – Klotho and FGF-23. These effects are important 
risk factors of cardiovascular complications that are the cause of significant lethality rate in 
such patients.  
3.5.2 Ectopic mineralization inhibitors 
Calcification inhibitors deficiency is an important factor of arterial calcification 
development. 
Matrix γ-Carboxyglutamic Acid Protein — MGP is a protein produced in bone tissue. It blocks 
the osteo-chondrocytous trans-differentiation of vascular smooth muscles cells into 
osteoblast-like cells. MGP also prevents the formation of crystallization areas in vascular 
tunica media and atherosclerotic plaques. It regulates the synthesis of skeletal matrix 
[Craver, 2007; London, 2000; National kidney Foundation. K/DOQI Clinical Practice 
Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease, 2003; 
Zemchencov,2009]. 
Osteopontin — acidic protein that is being expressed in arterial calcification areas. It activates 
osteoblasts and inhibits hydroxyl-apatite formation. Osteopontin enters the crystallization 
loci and inhibits their formation [National kidney Foundation. K/DOQI Clinical Practice 
Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease, 2003;  
Zemchencov,2009]. 
Osteoprotegrin — is expressed in atherosclerotic plaques and tunica media calcification loci. 
Osteoprotegrin inhibits the process of osteoclasts differentiation and the activity of bone 
alkaline phosphatase isoenzyme. Therefore, it hampers the process of tunica media and 
atherosclerotic plaques [Zemchencov,2009]. 
Protein  α2 Heremans-Schmid (Phetuin) — is a calcium-binding protein mostly produced in 
liver. Uremia is associated with significant decrease of this protein’s level. Experimental 
studies demonstrated that phetuin A binding results in vascular calcification. It is stored in 
smooth muscles and prevents their transformation into osteoblast-like cells 
[Zemchencov,2009]. 
Pyrophosphates suppress the osteo-chondrogenous trans-differentiation of vascular smooth 
muscles cells and formation of hydroxyl-apatite crystals. They are synthesized from 
nucleotide-triphosphates; the synthesis process is mediated by nucleotide-pyrophosphatase. 
In CKD patients the levels of nucleotide-pyrophosphatase and pyrophosphates carrier in 
tunica media are decreased. IGF-1 and N3 fatty acids inhibit the differentiation of vascular 
smooth muscles cells into osteoblast-like cells and tunica media calcification also [Craver 
,2007; National kidney Foundation. K/DOQI Clinical Practice Guidelines for Bone 
Metabolism and Disease in Chronic Kidney Disease, 2003; Zemchencov,2009]. 
3.5.3 Ectopic mineralization stimulators  
Hyper-phosphatemia causes the induction of osteoblastic differentiation factors - 
Cbfa1/Runx2, osteocalcin and sodium-dependent phosphate co-transporter type III — Pit-1. 
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Pit-1 expression is stimulated by high levels of extra-cellular calcium. Matrix vesicles and 
bone matrix proteins are secreted into the peri-vascular space; further they are subject to 
mineralization [  National kidney Foundation. K/DOQI Clinical Practice Guidelines for 
Bone Metabolism and Disease in Chronic Kidney Disease, 2003; KDIGO,2009;  
Zemchencov,2009 ]. 
3.6 Uremic toxins  
Uremic toxins cause the expression of Cbfa1/Runx2, osteopontin, bone AP isoenzyme and 
osteoprotegrin independently of phosphorus levels. They enhance the secretion of  
bone morphogenesis protein (BMP-2) by vascular smooth muscles cells and stimulate  
their mineralization. As renal failure progresses, new factors are added to arterial 
calcification process  [National kidney Foundation. K/DOQI Clinical Practice Guidelines for 
Bone Metabolism and Disease in Chronic Kidney Disease, 2003; KDIGO,2009; Moe , 2003; 
Sitara, 2003]. 
3.7 Oxidation stress and inflammation 
Uremic intoxication is associated with oxidation stress and systemic inflammation. The 
latter one jeopardizes oxidation stress, typical for uremia. Formation of oxidants contributes 
to high oxidation rate of lipoproteins that enhance the transformation of vascular smooth 
muscle cells into osteoblast-like ones. VSMC osteoblastic transformation is stimulated by 
glucocorticosteroids, leptin and hyperglycemia  [KDIGO,2009]. 
3.8 Vitamin D metabolism disorders 
Vitamin D has been reported to contribute to regulation of VSMC activity and metabolism. 
Vascular smooth muscle cells express 1ǂ-hydroxylase to convert 25(OH)D3 into 1,25(OH)2D3; 
they also express vitamin D receptors (VDR). Calcitriol stimulates the VDR expression on 
smooth muscle cells. VDR is the factor of smooth muscles proliferation and differentiation. 
Depending on plasma levels, calcitriol can both stimulate and inhibit the proliferation of 
vascular smooth muscles cells. Calcitriol levels 10–7–10–10 M stimulates vascular calcification 
in a dose-dependent way by increasing the ratio “nuclear factor receptor activator/ 
osteoprotegrin”.  
In CKD experimental models calcitriol analogues (paricalcitol and doxercalciferol) caused 
lesser vascular calcification compared to similar doses of calcitriol. Unlike calcitriol, 
paricalcitol didn’t cause any increase of Cbfa1/Runx2 and osteocalcin expression rate. Doses 
of calcitriol and its analogues used in doses sufficient for iPTH hyper-production 
suppression prevented vascular calcification; however, higher doses of the drugs stimulated 
calcification [Craver ,2007; Finch,2010; National kidney Foundation. K/DOQI Clinical 
Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease, 2003; 
Zemchencov, 2009]. 
Study with 520 CKD patients (median follow-up 21 years) with mean GFR 30 ml/min/1,73 
m2 demonstrated that calcitriol treatment was associated with lethality rate decrease. Similar 
study demonstrated comparable results [National kidney Foundation. K/DOQI Clinical 
Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease, 2003]. 
Therefore, recent studies demonstrated that in CKD patients high doses of calcitriol and its 
analogues can stimulate vascular calcification, while their moderate doses provide a 
protective effect through type I collagen and promoter gene core-binding factor-ǂ1 (Cbfa1) 
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production inhibition. Collagen type I is the basis for calcium deposits, while Cbfa1 
stimulates the production of type I collagen [Finch,2010; Moe , 2003; Sitara ,2003 ]. 
3.9 Clinical manifestations of soft tissues calcification 
Metastatic calcification is found in patients with secondary hyperparathyroidism and with 
adynamic skeletal diseases susceptible to hypercalcemia due to inability of bone tissue to 
accept surplus calcium. Hyperphosphatemia with elevated Ca2+ × Р5+ index (>55 mg2/dl2 or 
4,5–5,5 mmol2/l2), dialysis-associated alkalosis and local tissue damage promote formation 
of calcium phosphate deposits in soft tissues  [Craver ,2007; National kidney Foundation. 
K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney 
Disease, 2003; KDIGO,2009; Zemchencov,2009 ]. 
Soft tissues and vascular calcifications contain hydroxyl-apatite crystals with  Ca: Ǻg: Р 
ratio similar to bone; amorphous micro-crystals of calcium, magnesium and phosphates 
(CaǺg3(РǼ4)2) are found in muscles, heart and lungs. It is considered that the variability of 
calcification depends on local tissue factors – hydrogen ions, magnesium, calcium and 
phosphorus levels. Formation of hydroxy-apatite crystals is associated with significant 
fibrosis; while formation of amorphous crystals doesn’t result in fibrosis [Ermolenko, 2009; 
National kidney Foundation. K/DOQI Clinical Practice Guidelines for Bone Metabolism 
and Disease in Chronic Kidney Disease, 2003]. 
Formation of phosphorus and calcium salts deposits  in skin results in severe itching that is 
resolved only after parathyroidectomy [National kidney Foundation. K/DOQI Clinical 
Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease, 2003, 
KDIGO,2009; Zemchencov,2009]. 
Skin calcification. Calcium salts deposits in skin are associated with formation of maculae and 
vesicles containing solid structures. Calcium salts crystals can be found at biopsy. After 
subtotal parathyroidectomy skin deposits of calcium salts undergo regression; therefore, 
secondary hyperparathyroidism is the leading factor of skin calcification [Craver, 2007;  
Zemchencov, 2009]. 
Formation of skin ulcers and tissue necrosis (calciphylaxis). This syndrome was described by 
Seyle in 1962; the author named it calciphylaxia. Recently, most authors prefer the name 
calcifying uremic arteriopathy. This clinical syndrome is characterized by progressing skin 
ischemia, affecting fingers of hands and feet, hips and ankles. It develops in patients 
receiving dialysis on a regular basis for 10 years and more. It is less frequent in patients 
receiving peritoneal dialysis. The syndrome is characterized by vascular calcification and 
sub-periosteum bone resorption. Painful erythematous subcutaneous vesicles or blue 
maculae are followed by ulceration or necrosis. Reynaud’s syndrome can precede the 
affection of fingers of hands and feet. Ulcers develop slowly (for several months) or fast 
(within several weeks). Concomitant infections can result in fatal sepsis [National kidney 
Foundation. K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in 
Chronic Kidney Disease, 2003, KDIGO,2009; Zemchencov,2009]. 
The treatment strategy is not established yet. Local treatment is ineffective; in most patients 
subtotal parathyroidectomy resulted in calciphylaxia regression, however, in some patients 
skin lesions persisted or even progressed.  
Mineral metabolism disorders with secondary hyperparathyroidism and vascular 
calcification, local tissue lesions, obesity (especially in white females), vitamin C deficiency 
predispose to development of this syndrome. Vitamin C deficiency in CKD patients was 
reported to result in hyper coagulation; therefore vascular occlusions and tissue necrosis 
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occur. However, administration of warfarin results in progression of skin lesions in these 
patients. Local tissue lesions at insulin, heparin or dextran administration sites are usual 
locations of ulceration or skin necrosis [Craver ,2007;   National kidney Foundation. 
K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney 
Disease, 2003; KDIGO,2009]. 
Calcification of eyes. Conjunctiva and corneal calcium deposits associated with vascular 
inflammation result in “red eyes” syndrome. This transient process recurs as  
new conjunctiva calcium deposits are formed  [National kidney Foundation. K/DOQI 
Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease, 
2003]. 
Conjunctiva deposits of calcium salts can be symptoms-free. In such cases they are found 
during ophthalmologic examination. Calcium salts deposits are represented by white 
plaques or small dot-like deposits on lateral or medial segments of the conjunctiva. They are 
also found on cornea or lateral/medial segments of eye border (band-like keratopathy). 
Calcium deposits in eye blood vessels result in local pH increase due to CO2 loss through 
the conjunctiva surface [Zemchencov,2009 ]. 
Visceral calcification. Usually calcium salts deposits are found in lungs, stomach, heart, 
skeletal muscles and kidneys. Usually calcifications can’t be determined by standard X-ray; 
however, they are found during isotope scanning with 99mTc – pyrophosphate. Calcifications 
of lungs and heart can result in severe or fatal complications. Cases of pulmonary 
calcifications resulting in severe pulmonary fibrosis, pulmonary hypertension and left 
ventricle hypertrophy have been reported. Heart and lungs calcifications are one of the main 
causes of morbidity and mortality in dialysis patients [Craver ,2007; National kidney 
Foundation. K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in 
Chronic Kidney Disease, 2003 , Zemchencov, 2009; Huang Chou-Long, 2010]. 
High level of dietary vitamin C that is being metabolized into oxalates can result in calcium 
oxalate deposits formation in soft tissues, heart, mitral and aortal valves, resulting in 
cardiomyopathy and fatal heart failure [National kidney Foundation. K/DOQI Clinical 
Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease, 
2003;KDIGO,2009]. 
Peri-articular calcification. Calcium salts deposits formation in peri-articular space results in 
limited mobility and tendovaginitis. Affected joints contain transparent synovial with 
normal viscosity and cell counts [Darry ,2008; Masuyama,2006; National kidney Foundation. 
K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney 
Disease, 2003;KDIGO,2009]. This acute condition is called calcifying peri-arthritis. Uric acid 
salts are also found in the peri-articular tissues (secondary gout). This condition is often 
associated with chondro-calcinosis. Pseudo-gout is diagnosed when pyro-phosphate 
crystals are found in synovial cells. The study including 135 dialysis patients demonstrated 
the increase of peri-articular calcification rate from 9 to 42% from dialysis year 1 to dialysis 
year 8 [Zemchencov,2009]. 
Some dialysis patients develop large tumor-like formations in the peri-articular regions. 
They contain encapsulated lime fluid and soft calcium-based substance. Usually these 
formations are painless; however, their size can limit the mobility of the joint. Tumor-like 
calcium deposits can regress if serum phosphorus is adequately controlled by phosphorus 
binders or after subtotal parathyroidectomy [Craver ,2007; National kidney Foundation. 
K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney 
Disease, 2003; Zemchencov,2009]. 
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4. Prevention and treatment of CKD associated phosphorus and calcium 
metabolism disorders 
4.1 Diet and phosphate binders 
Low phosphate diet and/or phosphate binders are considered to be an important 
therapeutic approach targeted to prevent life-threatening complications in CKD patients. 
According to K/DOQI Practical Clinical Recommendations, daily phosphorus uptake 
should be limited to 800-1000 mg (adjusted by requirement in protein) in CKD III-IV 
patients with serum phosphorus level over 4.6 mg/dl (1.49 mmol/l) and over 5.5 mg/dl 
(1.78 mmol/l) in dialysis patients or in patients with plasma iPTH level exceeding normal 
limits established for corresponding CKD stages [Craver ,2007; National kidney Foundation. 
K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney 
Disease, 2003]. If dietary phosphorus limitations are insufficient to control phosphorus and 
iPTH levels, phosphate binders are recommended [Moore, 2010; Wang, 2006]. Long-term 
administration of calcium-based phosphate binders can result in hypercalcemia. Calcium 
carbonate – associated hypercalcemia is found 3.5 fold more frequent compared to calcium 
acetate associated hypercalcemia because calcium carbonate interacts with phosphorus at 
pH 5.0, when its dissolution rate is decreased [Ketteler,2011; Zemchencov,2009]. Calcium – 
based phosphate binders decrease the serum phosphorus level effectively and can be used 
for initial phosphate-binding treatment. Total daily dose of elementary dietary calcium 
should be within 1.5 g/day [National kidney Foundation. K/DOQI Clinical Practice 
Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease, 2003]. Calcium 
based phosphate binders should not be used in dialysis patients with hypercalcemia 
(adjusted total serum calcium level over 10.2 mg/dl or 2.54 mmol/l) and in patients with 
plasma PTH level under 130 pg/ml (14.4 pmol/l) as measured by 2 consequent analyses 
[Craver, 2007; Moore, 2010;KDIGO,2009]. Calcium-free phosphate binders should be used in 
these patients. At present, sevelamer hydrochloride (renagel) is widely used in clinical 
setting for binding of dietary phosphates. Renagel is synthetic calcium- and hydroxyl-
aluminum free drug. It is not absorbed in gastro-intestinal tract. The drug decreases plasma 
levels of iPTH, phosphorus and Ca×P index; it also corrects the dyslipidemia [Craver 
,2007;KDIGO,2009]. The drug administration does not result in calciemia, therefore its 
combinations with active vitamin D analogues are safe. Renagel is effective for control of 
vascular and soft tissues calcification. Renagel is indicated for to patients with elevated 
serum phosphorus level and total adjusted calcium level over 5.5 and 10.2 mg/dl, 
respectively, and iPTH level decrease under 130 pg/ml and metastatic calcification [Craver 
,2007; KDIGO,2009]. Long-term Renagel administration can result in decrease of 
furosemide’s diuretic effect and hypochloremic acidosis associated with bicarbonates loss 
[Craver ,2007; Block ,2010; Reddy ,2009]. Table 3 represents the pattern of sevelamer 
hydrochloride dosage choice based on serum phosphorus level.  
 
Serum phosphorus level Sevelamer hydrochloride dosage (800 mg tablets) 
6–7,5 mg/dl (1,94–2,42 mmol/l) 1 tablet × 3 times per day 
> 7,5 mg/dl (2,42 mmol/l) 2 tablets × 3 times per day 
Table 3.  Sevelamer hydrochloride dosage choice based on serum phosphorus level 
Equivalent doses of sevelamer hydrochloride (calculated in mg/kg) are used for transfer 
from calcium-based phosphate binders. Sevelamer hydrochloride dosage is 800 tablet per 
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one meal [National kidney Foundation. K/DOQI Clinical Practice Guidelines for Bone 
Metabolism and Disease in Chronic Kidney Disease, 2003; KDIGO,2009]. In USA and 
Europe lactane (Fosrenol) carbonate is used for phosphate binding in gastro-intestinal tract. 
500, 750 and 1000 mg Fosrenol tablets are available. Treatment course continues until 
normal phosphorus level is reached (1.13 – 1.78 mmol/l; 3.5 – 5.5 mg/dl). Maximum daily 
dosage – 3750 mg (for short-term treatment – 5-7 days). However, lactane is subject to 
partial absorption and can accumulate in bone tissue [Craver ,2007; Moore, 2010]. At present 
sevelamer carbonate and Zerenex phosphate binder, containing inorganic iron compounds 
are being studied. Preliminary data indicate similar efficacy to calcium salts [Craver ,2007; 
National kidney Foundation. K/DOQI Clinical Practice Guidelines for Bone Metabolism 
and Disease in Chronic Kidney Disease, 2003; Volgina, 2004]. 
In patients receiving peritoneal dialysis phosphorus elimination rate can be increased by 
replacement of cellulose acetate membranes by poly-sulfone membranes or by switching to 
hemodiafiltration with higher phosphorus clearance compared to dialysis. Enhanced blood 
flow in the hemodialysis apparatus results in increased creatinine clearance; however, it 
does not change the phosphorus elimination rate. On the other hand, dialysis prolongation 
(transfer from 3 times per week regimen to daily dialysis) results in 30% decrease of the pre-
dialysis serum phosphorus level and enables reduction of phosphate binders administration 
frequency [Craver ,2007; National kidney Foundation. K/DOQI Clinical Practice Guidelines 
for Bone Metabolism and Disease in Chronic Kidney Disease, 2003]. In patients receiving 
peritoneal dialysis frequent exchange of dialysis solution in peritoneal cavity results in 
higher creatinine and phosphorus clearance. Total adjusted plasma calcium level should be 
maintained within normal limits (8.4 – 9.5 mg/dl or 2.1 – 2.37 mmol/l) [1]. In dialysis 
patients receiving calcium-based phosphate binders and active vitamin D metabolites dose 
reduction or drug withdrawal is recommended when the total adjusted calcium serum level 
exceeds 10.2 mg/dl (2.54 mmol/l). Dosages should be suspended until total adjusted serum 
calcium level returns to normal. If these measures are ineffective, dialysis fluid with low 
calcium level (1.5 – 2.9 mEq/l) should be used for 3-4 weeks. Phosphorus-calcium ratio 
should be kept under 55 mg2/dl2. This can be achieved through serum phosphorus level 
maintenance within the target limits [Craver ,2007; National kidney Foundation. K/DOQI 
Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease, 
2003, Volgina, 2004].  
Hyperphosphatemia control enables FGF-23 level decrease in CKD patients. Elevated FGF-
23 serum level is associated with higher mortality rate in patients with terminal CKD. The 
possibility of using neutralizing antibodies for excessive FGF-23 production control is under 
discussion. However, the clinical benefit of this method is not clear yet [ Yamazaki ,2008].  
Hypocalcemia treatment should include oral calcium salts – e.g., calcium carbonate and/or 
vitamin D active metabolites [Craver ,2007; National kidney Foundation. K/DOQI Clinical 
Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease, 2003]. 
4.2 Vitamin D active metabolites 
When iPTH plasma level exceeds the target limits established for corresponding CKD stage 
and the 25(Ǽǻ)D3 level is under 30 ng/ml, treatment with vitamin D2  should be initiated. It 
is considered, that at early CKD stages ergocalciferol is safer compared to calciferol [Craver, 
2007; Moore,2010; National kidney Foundation. K/DOQI Clinical Practice Guidelines for 
Bone Metabolism and Disease in Chronic Kidney Disease, 2003, Volgina, 2004]. Dose 
adjustment should be based on the rate of 25(Ǽǻ)D3 deficiency. If the 25(Ǽǻ)D3 level is 
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under 15 ng/ml (37 nmol/l), 50 000 IU/week × 4 weeks ergocalciferol dosage regimen 
should be used; later the 50 000 IU/month × 4 months regimen is used. If  25(Ǽǻ)D3 serum 
level is 20-30 ng/ml (50-75 nmol/l), 50 000 IU × 1 month treatment regimen should be used 
for 6 months [Craver ,2007; National kidney Foundation. K/DOQI Clinical Practice 
Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease, 2003; 
KDIGO,2009].  Treatment with vitamin D is recommended for patients with pre-dialysis 
stages of CKD with a normal 25(Ǽǻ)D3  levels (over 30 ng/ml or 75 nmol/l) and decreased 
plasma level of as adjusted total calcium, elevated serum iPTH level and normal serum 
phosphorus level. Active vitamin D metabolites (calcitriol, alpha-caclidol or doxecalciferol) 
are more effective for iPTH synthesis and secretion suppression [Craver ,2007; National 
kidney Foundation. K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease 
in Chronic Kidney Disease, 2003; KDIGO,2009; Volgina, 2004]. Lower initial dosages are 
recommended (see Table 4).  
 
iPTH plasma level, 
pg/ml [pmol/l] 
Serum level 
Calcitriol or alpha-
calcidol, orally 
Doxecalciferol, 
orally 
Ca, mg/dl 
[mmol/l] 
P, mg/dl 
[mmol/l] 
> 70 [7,7] 
(CKD III) or > 110 
[12,1] (CKD IV) 
< 9,5 [2,37] < 4,6 [1,49] 0,25 mcg/day 
2,5 mcg 3 times per 
week 
Table 4.  Serum iPTH, adjusted total calcium and phosphorus levels requiring vitamin D 
active metabolites. Initial doses for patients with CKD stages III – IV  
Calcitriol dosage should be within 0.5 mcg/day, except for cases, when the adjusted total 
calcium level increase is under 0.2-0.3 mg/dl/month. [Craver ,2007; Moore,2010;  National 
kidney Foundation. K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease 
in Chronic Kidney Disease, 2003 KDIGO, 2009;]. Treatment with active vitamin D 
metabolites should be conducted only in patients with adjusted total calcium serum level 
under 9.5 mg/dl (2.37 mmol/l) and serum phosphorus level under 4,6 mg/dl (1.49 mmol/l) 
[ National kidney Foundation. K/DOQI Clinical Practice Guidelines for Bone Metabolism 
and Disease in Chronic Kidney Disease, 2003; KDIGO,2009; Zemchencov,2009 ]. Patients 
receiving hemodialysis or peritoneal dialysis with serum iPTH level over 300 pg/ml (33.0 
pmol/l) should receive active vitamin D metabolites (e.g., calcitriol, alpha-calciferol, 
paricalcitol, doxecalciferol, see Table 5) in order to decrease serum iPTH level up to target 
level 130–300 pg/ml (14,4–33,0 pmol/l) [Craver ,2007; National kidney Foundation. 
K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney 
Disease, 2003, KDIGO,2009; Volgina, 2004]. 
In patients receiving peritoneal dialysis oral calcitriol or doxecalciferol dosages are 0.5-1.0 
and 2.5-5.0 mcg 2-3 times per week, respectively [Craver ,2007; National kidney Foundation. 
K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney 
Disease, 2003;KDIGO,2009]. Alternative regimen of oral calcitriol is 0.25 mcg daily [National 
kidney Foundation. K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease 
in Chronic Kidney Disease, 2003; KDIGO,2009]. During the initial stage of active vitamin D 
metabolites or during the dosage increase period serum phosphorus and calcium levels 
should be monitored each 2 weeks throughout the first month; monthly monitoring is 
recommended later [Craver ,2007; National kidney Foundation. K/DOQI Clinical Practice 
Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease, 2003;KDIGO,2009].  
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iPTH, pg/ml 
[pmol/l] 
Ca, mg/dl 
[mmol/l] 
P, mg/dl 
[mmol/l] 
Ca-P Calcitriol Paricalcitol Doxecalciferol 
300–600  
[33–66] 
< 9,5 [2,37] < 5,5 [1,78] < 55 
0,5–1,5 mcg, 
i/v 
0,5–1,5 mcg 
orally 
2,0–5,0 mcg, 
i/v 
5 mcg, orally 
2 mcg, i/v 
600–1000  
[66–110] 
< 9,5 [2,37] < 5,5 [1,78] < 55 
1,0–3,0 mcg, 
i/v 
1,0–4,0 mcg, 
orally 
6,0–10,0 mcg, 
i/v 
5–10 mcg, 
orally 
2–4 mcg, i/v 
> 1000 [110] <10 [2,5] < 5,5 [1,78] < 55 
3,0–5,0 mcg, 
i/v 
3,0–7,0 mcg, 
orally 
10,0–15,0 
mcg, i/v 
10–20 mcg, 
orally 
4–8 mcg, i/v 
Table 5. Recommended initial doses of active vitamin D metabolites – based on iPTH, 
phosphorus and calcium serum levels and Ca×Р index in patients receiving dialysis 
In most patients effective suppression of iPTH secretion results in recovery of parathyroid 
glands hyperplasia [National kidney Foundation. K/DOQI Clinical Practice Guidelines for 
Bone Metabolism and Disease in Chronic Kidney Disease, 2003]. High concentrations of 
1,25(OH)2D3 stimulate apoptosis of parathyroid gland cells [Craver ,2007; Moore,2010]. This 
effect is used for “drug parathyroidectomy”, when 1,25(OH)2D3 is injected into the 
hyperplasic parathyroid glands [National kidney Foundation. K/DOQI Clinical Practice 
Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease, 2003, Volgina, 
2004].  Paricalcitol, or 1,25(Ǽǻ)2D2 is effective for iPTH suppression. Paricalcitol is selective 
active vitamin D metabolite with modified lateral chain (D2) and A ring (19-nor). Paricalcitol 
(Zemplar) selectively induces VDR (S-VDRA) gene expression in parathyroid glands, 
suppresses iPTH secretion without activation of intestinal VDR. The drug has no effect on 
bone resorption, therefore, it causes hypercalcemia less frequently compared to non-
selective active vitamin D metabolites. Unlike calcimimetics, paricalcitol possesses 
significant pleyotropic effects that provide the decrease of cardiovascular complications risk 
and inhibit CKD progress (anti-proteinuria effect). The anti-proteinuria effect of paricalcitol 
has been demonstrated in 3 double blind randomized placebo-controlled studies enrolling 
220 patients with CKD III-IV and hyperparathyroidism [Ermolenko, 2009]. By the end of 
week 24, proteinuria level decrease was demonstrated in 51% of patients receiving 
paricalcitol and in 25% of patients from placebo group (p  0.004). PTH level 30% decrease 
was found in 91% of patients receiving paricalcitol compared to 13% of patients in placebo 
group   (p<0,001). Decreased level of intact PTH <110 pg/ml was found in 75% of patients 
from paricalcitol group and in 12% of patients from placebo group [KDIGO,2009]. Our 
study that enrolled 50 CKD III-IV patients with systemic diseases (35 patients – lupus 
erythematous, 15 patients – different types of vasculites) had similar results. Patients were 
randomized in 2 groups; calcitriol 0.35 mcg/day was used in Group 1, paricalcitol 1 
mcg/day – in Group 2. Prior to treatment, proteinuria levels were 1.2 +/- 0.6 g/day in 
Group 1 and 1.3 +/- 0.4 in Group 2; iPTH levels were 75 +/- 17.4 pg/mal and 80 +/- 16.6 
pg/ml, respectively. Calcinosis/atherosclerosis of carotids was found in 27.3% of patients in 
Group 1 and in 33.3% of patients in Group 2. Calcitriol and paricalcitol were generally well 
tolerated. As a result, iPTH plasma levels reached normal levels after 3 months of treatment 
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in patients with elevated iPTH levels at baseline. In patients receiving paricalcitol, proteinuria 
level decrease occurred faster (p<0.05) and the arterial hypertension decrease by the end of 
Month 3 was more pronounced (p<0.01) compared to patients receiving calcitriol. In 4 of 12 
patients from Group 2 with diagnosed atherosclerosis/calcinosis, no episodes of 
hypercalcemia or signs of atherosclerosis/calcinosis were reported. Hypercalcemia episodes 
were reported in 27.3% of patients receiving calcitriol; progressing of atherosclerosis/ 
calcinosis diagnosed at baseline was reported in 3 patients [Milovanova, 2011].   
Paricalcitol is manufactured as 1, 2 and 4 mcg capsules or 1 ml (5 mcg) ampoules. Capsules 
are indicated for treatment and prophylaxis of secondary hyperparathyroidism associated 
with CKD III, IV and V; ampoules are indicated to patients with CKD V. In patients 
receiving peritoneal dialysis, the drug should be administered through slow intravenous 
injections (minimum duration – 30 seconds) in order to minimize the infusion-associated 
pains. Recommended initial dose of paricalcitol is 0.04 – 0.1 mcg/kg. Paricalcitol dose choice 
depends on baseline iPTH level: initial dose (mcg) = iPTH (pg/ml)/80. The drug is 
administered as bolus injections; within at least 1 day after dialysis. Paricalcitol capsules are 
administered once per day, every day or 3 times per week [KDIGO,2009]. The results of 3 
prospective randomized multicenter studies demonstrate that paricalcitol effectively 
suppresses iPTH secretion, decreases the activity of bone AP isoenzyme and decreases the 
plasma level of osteocalcin. These effects are indicative of bone resorption rate decrease 
[Moore, 2010].  
In patients with CKD III-IV with iPTH plasma level over 70 pg/ml (7.7 pmol/l) and 110 
pg/ml (12.1 pmol/l) receiving low phosphorus diet, paricalcitol, calcitriol, alpha-calcidol or 
doxecalciferol are recommended for treatment and prophylaxis of bone disease (see Table 5) 
[KDIGO,2009]. In patients with CKD V and iPTH plasma level over 300 pg/ml (33.0 pmol/l) 
with renal osteodystrophy paricalcitol, calcitriol, doxecalciferol and alpha-calcidol are 
recommended to suppress the excessive iPTH secretion and normalize the elevated 
metabolic profile of bone tissue [Craver, 2007;KDIGO,2009;  Slinin,2005].  
5. Summary 
Phosphorus metabolism disorders play an important role in CKD pathogenesis. Therefore, 
early control of hyperphosphatemia is required to improve the quality of life in CKD 
patients. Numerous cohort studies have shown associations between disorders of mineral 
metabolism, cardiovascular disease and mortality. These observational studies have 
broadened the focus of CKD-related mineral and bone disorders to include cardiovascular 
disease ( which is the leading cause of death in patients at all stages of CKD). All three of 
these processes ( abnormal mineral metabolism, abnormal bone and extra skeletal 
calcification) are closely interrelated and together make a major contribution to the 
morbidity and mortality of patients with CKD. Mechanisms of CKD-associated extra-osseal 
calcification are complicated and multi-factorial. Recently, new mediators of osteogenesis-
angiogenesis interactions have been identified – they are hypoxia – induced factor 1-ǂ 
(HIF1-ǂ) and vascular endothelium growth factor (VEGF). These factors induce vascular 
calcification through angiogenous signaling. New factors produced by kidneys and bone 
tissue have been identified. They are morphogenetic proteins (FGF-23 and Klotho) that 
contribute to phosphorus and vitamin D turnover and bone mineralization regulation. It has 
been suggested that resistance to FGF-23 is one of the early manifestations of CKD-
associated metabolic disorders. This effect is mediated through decreased renal expression 
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of Klotho. It has been reported that calcitriol and paricalcitol increase the rate of Klotho 
expression in kidneys. The possibility to use anti-FGF neutralizing antibodies to control 
FGF-23 hyperproduction is under discussion. However, further studies are required to 
evaluate their effects related to the system of complicated interactions between bone tissue, 
kidneys and parathyroid glands.  
5.1 Recommendations for further research  
Further research is needed to determine the reference values of corrected total serum 
calcium levels, depending on age, sex and race of patients with CKD and dialysis patients. 
Also, research is needed to determine the adequate calcium intake, the timing of the therapy 
with calcium and used calcium supplement drugs. 
Very interesting is the new vitamin D metabolites testing, which are less likely to cause 
hypercalcemia. The ideal aim of such trials is to reduce serum IPTG levels  with an 
insignificant change in serum calcium concentration. It would be useful to evaluate the 
relationship between serum IPTG levels and histological stage of hyperparathyroid bone 
disease in relation to the degree of renal failure progression. 
Regulation of the IPTG level is a complex task. Need to find an acceptable balance between 
adequate levels of IPTG, accompanied by no bone lesions, and prevention of accelerated 
calcinosis / atherosclerosis 
It is neededto carry out long-term studies evaluating the efficacy, side effects and impact on 
morbidity and mortality of various phosphate-binding drugs. Although the recently 
completed studies have demonstrated the benefits of sevelamer compared with calcium 
phosphate binders in prevention of aortic and coronary artery calcification progression in 
patients with CKD stage 4, research evaluating a positive impact on cardiovascular 
morbidity and mortality in dialysis patients is needed.  
The next perspectives of controlled clinical trials in nephrology are associated primarily 
with the cooperation of medical, educational and scientific centers, including online, on the 
basis of professional social organizations. This interaction can intensify the integration of 
nephrologists in international clinical research, to organize the original clinical research on 
common standards( Good Clinical Practice, Good Research Practice), involving the 
maximum number of nephrology, outpatient and inpatient treatment centers. 
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